Find related articles on

Latest News

RSS

New reviews and commentaries, 5 January 2007

5 January 2007   |   Reviews & commentaries

Overview of the pharmacoeconomics of pharmacogenetics. Dervieux T, Bala MV (2006) Pharmacogenomics 7(8):1175-1184. Review of pharmacoeconomics looking at how genetic markers of drug efficacy and toxicity may be used cost-effectively for improved patient care, with examples (PubMed).

Pharmacogenetics of irinotecan: clinical perspectives on the utility of genotyping. Innocenti F, Ratain MJ (2006) Pharmacogenomics 7(8):1211-1221. Perspective article on UGT1A1 genotyping prior to the use of irinotecan to prevent toxicity (PubMed).

Pharmacogenomics of asthma. Pahl A, Benediktus E, Chialda L (2006) Curr Pharm Des12(25):3195-206. Review looking at polymorphisms that influence the asthma therapy, and the potential benefits of genomic expression studies using microarray technology (PubMed).

Genetic testing without consent: the implications of the new Human Tissue Act 2004. Lucassen A and Kaye J (2006) J Med Ethics 32(12):690-2. Commentary expressing concern about the HTA’s provision for DNA analysis without consent when an individual has yet to make a decision, and calling for new guidelines for this situation (PubMed).
 
Exploring the uses of RNAi - gene knockdown and the Nobel Prize. Bernards R (2006) N Engl J Med 355(23):2391-3. Perspective article on RNA interference and its applications in ‘knockdown’ of gene expression (PubMed).
 
Unraveling the Genetics of Human Obesity. Mutch DM and Clement K (2006)PLoS Genet 2(12):e188. Review on the insights into the physiology of obesity provided by rare genetic disorders, and on emerging understanding of key genetic and environmental interactions involved in different forms of obesity (PubMed).

The genetics of fibromyalgia syndrome. Buskila D, Sarzi-Puttini P, Ablin JN (2007) Pharmacogenomics 8(1):67-74. Review of the role of genetic polymorphisms in predisposition to FMS and the scope for future genetic studies (PubMed).

Vascular endothelial growth factor pharmacogenetics: a new perspective for anti-angiogenic therapy. Pasqualetti G, Danesi R, Del Tacca M, Bocci G (2007) Pharmacogenomics 8(1):49-66. Review of clinical genetic studies of antigentic determinants, proposing that pharmacogenetic profiling of patients prior to the use of anti-angiogenic drugs could be beneficial (PubMed).

From molecular diagnostics to personalized testing. Finan JE, Zhao RY (2007) Pharmacogenomics 8(1):85-99. Review of the future of molecular-based testing and prospects for a transition towards personalised medicine (PubMed).
 
Predicting risk of breast cancer recurrence using gene-expression profiling. Ignatiadis M, Desmedt C (2007) Pharmacogenomics 28(1):101-11. Special report on molecular profiling of breast tumors using microarray technology, and the potential to integrate information about prognostic genetic signatures, pharmacogenetics and clinical parameters to create a decision-making algorithm for management (PubMed).

Unraveling the genetics of atherosclerosis: implications for diagnosis and treatment. Seo DM, Goldschmidt-Clermont PJ (2007) Expert Rev Mol Diagn. 7(1):45-51. Review of different approaches for studying the genetics of atherosclerosis and the implications clinical practice (PubMed).

Keywords: Reviews & Commentaries